EIF2B3

Across TCGA pan-cancer cohorts, EIF2B3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF2B3 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EIF2B3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EIF2B3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where EIF2B3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.487	0.876	<.001	27	view →
PDAC	DFS	Median	II,III,IV	0.478	0.249	.001	8	view →
HNSC	DFS	Median	III,IV	0.703	0.856	.018	2	view →
LUAD	DFS	Quartile	All	0.995	0.889	.025	1	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EIF2B3–CCRCC (OS)

Open the CCRCC breakdown →